Article
Oncology
Samuel Peter Heilbroner, Reed Few, Judith Mueller, Jitesh Chalwa, Francois Charest, Somasekhar Suryadevara, Christine Kratt, Andres Gomez-Caminero, Brian Dreyfus, Tomas G. Neilan
Summary: The study used a machine learning model to predict cardiac events risk factors in patients receiving immune checkpoint inhibitors therapy, including increased age, corticosteroids, laboratory abnormalities, cardiac history, extremes of weight, decreased lymphocyte percentage, and increased neutrophil percentage.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Dermatology
Ji-Hye Park, Dokyoung Yoon, Jeeyun Lee, Se Jin Oh, Hyun Je Kim, Jong Hee Lee, Dong-Youn Lee
Summary: PD-1/PD-L1 inhibitors have shown efficacy in treating various malignancies, but their immunomodulatory activities can lead to unpredictable cutaneous adverse events (CAE). This study identified characteristics of CAE in patients treated with these inhibitors and found that melanoma patients were more prone to CAE, with acneiform eruptions more common in those under 60 years old. Overall survival times did not significantly differ between patients with and without CAE.
JOURNAL OF DERMATOLOGY
(2021)
Review
Medicine, Research & Experimental
Sheng-Kai Hsu, Chia-Yang Li, I-Ling Lin, Wun-Jyun Syue, Yih-Fung Chen, Kai-Chun Cheng, Yen-Ni Teng, Yi-Hsiung Lin, Chia-Hung Yen, Chien-Chih Chiu
Summary: New types of programmed cell death, such as ferroptosis, necroptosis, and pyroptosis, have emerged in recent years, playing significant roles in cancer progression modulation and being closely related to immune regulation in the tumor microenvironment. Pyroptosis, in particular, has been identified as crucial for host defense and bridging innate and adaptive immunity, showing benefits for cancer immunotherapies.
Article
Immunology
Athitaya Luangnara, Salin Kiratikanon, Thanika Ketpueak, Thatthan Suksombooncharoen, Chaiyut Charoentum, Busyamas Chewaskulyong, Napatra Tovanabutra, Siri Chiewchanvit, Surapon Nochaiwong, Mati Chuamanochan
Summary: This study investigated the incidence and associated factors of cutaneous immune-related adverse events (cirAEs) among cancer patients in northern Thailand, and found that the incidence of cirAE-related ICI therapy was comparable to that in white populations. Age over 75 and pre-existing chronic kidney disease stages 3-4 were identified as prognostic risk factors for cirAE-related ICI therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
Summary: This study of 125 patients suggests a positive impact of ICI on overall survival in aLCNEC, despite the limitations of retrospective design and small sample size.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Tianqi Liu, Chen Zhu, Xin Chen, Gefei Guan, Cunyi Zou, Shuai Shen, Jianqi Wu, Yuhang Wang, Zhiguo Lin, Ling Chen, Peng Cheng, Wen Cheng, Anhua Wu
Summary: This study reveals the importance of ferroptosis in glioma and proposes a novel immunotherapeutic strategy that combines immune checkpoint blockade treatment with ferroptosis inhibition, showing a synergistic therapeutic effect.
Article
Oncology
Alok A. Khorana, Jennell Palaia, Lisa Rosenblatt, Radhika Pisupati, Ning Huang, Chi Nguyen, John Barron, Kerrin Gallagher, T. Christopher Bond
Summary: This study assessed the incidence and risk factors of venous thromboembolism (VTE) in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI). The study found that ICI-based regimens were associated with lower risk of VTE compared to chemotherapy (chemo), while the risk of VTE with ICI+chemo regimens was similar to chemo. Previous radiation and severe obesity were also associated with VTE.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Diana Maslov, Karine Tawagi, K. C. Madhav, Victoria Simenson, Helen Yuan, Cameron Parent, Adi Bamnolker, Richa Goel, Zoe Blake, Marc R. Matrana, Daniel H. Johnson
Summary: In this retrospective study, patients who received corticosteroids (CS) concurrently with immune checkpoint inhibitors (CPIs) were divided into two cohorts based on the timing of CS initiation. The results showed that delaying the use of CS during CPI treatment significantly improved CPI efficacy. Further prospective validation is needed to confirm these findings, and future studies should investigate the immune mechanisms by which corticosteroids affect T-cell function early in CPI treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Alexander Coukos, Julien Vionnet, Michel Obeid, Hasna Bouchaab, Solange Peters, Sofiya Latifyan, Alexandre Wicky, Olivier Michielin, Haithem Chtioui, Darius Moradpour, Francois Fasquelle, Christine Sempoux, Montserrat Fraga
Summary: This study compared the clinical, laboratory, and histological features of immune-related adverse events (irAEs) affecting the liver induced by immune checkpoint inhibitors (ICIs) with autoimmune liver diseases (AILD). The results showed distinct histological features between irAEs and AILD, suggesting different immunological mechanisms. The pattern of liver function test alteration could predict the type of irAEs, but not the histological severity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Chiara Pozzessere, Romain Lazor, Raphael Jumeau, Solange Peters, John O. Prior, Catherine Beigelman-Aubry
Summary: Pulmonary immune-related adverse events are rare but potentially severe side effects of immunotherapies. Accurate imaging evaluation is essential for prompt detection and correct management.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou
Summary: Peripheral T-cell lymphomas (PTCLs) are highly heterogeneous and immune checkpoint therapies, particularly PD-1/PD-L1 blockers, show promise as a treatment option for this disease. The clinical trials of these blockers have demonstrated good efficacy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Despina Michailidou, Ali Raza Khaki, Maria Pia Morelli, Leonidas Diamantopoulos, Namrata Singh, Petros Grivas
Summary: This study investigated the association between immune related adverse events (irAEs) and biomarkers in cancer patients receiving immune checkpoint inhibitors, identifying several risk factors. Patients with specific laboratory markers and clinical features had an increased risk of irAEs while lower NLR, MLR, and PLR were associated with longer overall survival. These findings suggest that baseline measurements and autoimmune history play a role in predicting irAEs and outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Yao Wang, Yimeng Wang, Jinming Yu, Xiangjiao Meng
Summary: Immune-checkpoint inhibitors have revolutionized the treatment of advanced non-small cell lung cancer, but the risk of immune-related adverse events, including checkpoint inhibitor pneumonitis, should not be ignored. The diagnosis and management of immune pneumonitis can be challenging due to its non-specific imaging features and symptoms, which may mimic other lung diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Lei Zhang, Yuankai Shi, Xiaohong Han
Summary: By integrating cellular and molecular factors, predictive factors for immune-related adverse events (irAEs) risk during anti-PD-1 immunotherapy across multiple cancer types were identified. These findings may deepen our understanding of irAEs pathogenesis and contribute to early detection and management of high-risk patients with irAEs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Lucas dos Santos, Carina M. Abrahao, William N. William
Summary: This article discusses the immune evasion and resistance mechanisms in head and neck squamous cell carcinomas, with a focus on the role of PD-L1 and PD-1 inhibitors in this disease. It also mentions research on predicting patient benefit from immunotherapy and studying resistance mechanisms, along with novel strategies to overcome resistance.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Ozguroglu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Summary: This phase II study aimed to evaluate the efficacy of lacnotuzumab added to gemcitabine plus carboplatin in patients with advanced triple-negative breast cancer. The results showed that lacnotuzumab + gem-carbo had comparable antitumor activity to gem-carbo alone, but with slightly poorer tolerability.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Nadege Bidan, Sainza Lores, Aure Vanhecke, Valerie Nicolas, Severine Domenichini, Rafael Lopez, Maria de la Fuente, Simona Mura
Summary: The study found that sphingomyelin nanosystems are promising carriers for efficient delivery of anticancer drugs. A 3D heterotype spheroid model of pancreatic tumor was constructed to investigate the potential of bare and polyethylene glycol modified lipid nanosystems in terms of their ability to penetrate the tumor mass and deliver drugs. The results showed that the lipid nanosystems successfully diffused through the spheroid without inducing toxicity, regardless of their surface properties. However, in the 3D tumor model, despite their efficient penetration capacity, the advantage of the nanosystems was lost when loaded with a lipid prodrug of gemcitabine. The 3D tumor model, being able to mimic the tumor and its microenvironment, provided a more realistic information on the cell sensitivity to treatments. The study highlights the importance of using appropriate 3D tumor models for proper in vitro evaluation of nanomedicine efficacy and their timely optimisation.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Mathematics
Adrian Gonzalez-Maestro, Elena Brozos-Vazquez, Balbina Casas-Mendez, Rafael Lopez-Lopez, Rosa Lopez-Rodriguez, Francisco Reyes-Santias
Summary: In this paper, the authors propose deterministic and stochastic mathematical programming models to distribute treatment schedules for patients in an oncology day hospital. The models consider constraints and uncertainties in the circuit, and also allow for the reorganization of medical appointments. The work is motivated by a real hospital and compared with data from the case.
Article
Pharmacology & Pharmacy
Raneem Jatal, Sofia Mendes Saraiva, Carlos Vazquez-Vazquez, Eric Lelievre, Olivier Coqueret, Rafael Lopez-Lopez, Maria de la Fuente
Summary: The accumulation of senescent cells can lead to the development of age-related diseases, including cancer. Research has found that the 4N1Ks peptide has the potential to target and eliminate senescent cells. However, peptide drugs have limitations that reduce their efficacy, so the study proposes the use of biodegradable nanosystems decorated with the 4N1Ks peptide. Experimental results show that these nanosystems have suitable properties and demonstrate improved therapeutic effects on cancer cells.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Dentistry, Oral Surgery & Medicine
Oscar Rapado-Gonzalez, Jose Luis Lopez-Cedrun, Ramon Manuel Lago-Leston, Alicia Abalo, Guillermo Rubin-Roger, Angel Salgado-Barreira, Rafael Lopez-Lopez, Laura Muinelo-Romay, Maria Mercedes Suarez-Cunqueiro
Summary: Differences in the concentration and integrity of cfDNA fragments in saliva have been found between oral squamous cell carcinoma (OSCC) patients and healthy individuals, indicating the potential of these markers as noninvasive biomarkers for OSCC diagnosis.
JOURNAL OF ORAL PATHOLOGY & MEDICINE
(2022)
Article
Dentistry, Oral Surgery & Medicine
Alejandro Lorenzo-Pouso, Susana B. Bravo, Javier Carballo, Maria del Pilar Chantada-Vazquez, Jose Bagan, Leticia Bagan, Cintia M. Chamorro-Petronacci, Mercedes Conde-Amboage, Rafael Lopez-Lopez, Abel Garcia-Garcia, Mario Perez-Sayans
Summary: This study investigated the salivary proteome in MRONJ patients and identified differentially expressed proteins. Three prioritized proteins were identified, which may serve as a potential biomarker panel for the prediction or diagnosis of MRONJ.
Article
Multidisciplinary Sciences
Martin Perez-Martelo, Alejandro Gonzalez-Garcia, Yolanda Vidal-Insua, Cristina Blanco-Freire, Elena Maria Brozos-Vazquez, Ihab Abdulkader-Nallib, Javier Alvarez-Fernandez, Hector Lazare-Iglesias, Carolina Garcia-Martinez, Yoel Z. Betancor, Maria Sanchez-Ares, Jose M. C. Tubio, Francisca Vazquez-Rivera, Sonia Candamio-Folgar, Rafael Lopez-Lopez, Juan Ruiz-Banobre
Summary: The study validates the prognostic significance of baseline PIV in patients with mCRC receiving first-line standard chemotherapy in a real-world scenario, suggesting the potential utility of PIV monitoring to anticipate disease progression among patients who achieve initial disease control.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Angela Rodriguez-Trillo, Carmen Pena, Samuel Garcia, Eva Perez-Pampin, Marina Rodriguez-Lopez, Antonio Mera-Varela, Antonio Gonzalez, Carmen Conde
Summary: This article investigates the role of ROCK in rheumatoid arthritis and finds that ROCK inhibition can significantly improve arthritis inflammation and bone erosion.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Patricia Mondelo-Macia, Jorge Garcia-Gonzalez, Alicia Abalo, Manuel Mosquera-Presedo, Santiago Aguin, Maria Mateos, Rafael Lopez-Lopez, Luis Leon-Mateos, Laura Muinelo-Romay, Roberto Diaz-Pena
Summary: This study confirmed the prognostic value of cfDNA quantitative analysis in SCLC patients before and during therapy, and developed a new risk prognostic model that can help identify patients who could benefit from current treatments.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Letter
Pathology
Patricia Mondelo-Macia, Ramon Manuel Lago-Leston, Aitor Rodriguez-Casanova, Alicia Abalo, Angel Diaz-Lagares, Jorge Garcia-Gonzalez, Luis Leon-Mateos, Roberto Diaz-Pena, Laura Muinelo-Romay
Article
Medicine, General & Internal
I Arias-de la Rosa, M. Ruiz-Ponce, L. Cuesta-Lopez, C. Perez-Sanchez, F. Leiva-Cepas, Md Gahete, P. Navarro, R. Ortega, J. Cordoba, E. Perez-Pampin, A. Gonzalez, A. J. Lucendo, E. Collantes-Estevez, Ch Lopez-Pedrera, A. Escudero-Contreras, N. Barbarroja
Summary: Rheumatoid arthritis patients may experience mild to moderate liver inflammation due to the infiltration of T, B cells, and macrophages, as well as the action of anticitrullinated protein antibodies (ACPAs). This phenomenon is independent of obesity or diabetes and is associated with systemic inflammation and disease activity levels.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Oncology
Juan Pardo-Montero, Isabel Gonzalez-Crespo, Antonio Gomez-Caamano, Araceli Gago-Arias
Summary: Prostate cancer is commonly treated with radiotherapy, including extreme hypofractionation. However, the response of prostate cancer to large radiation doses per fraction may differ from the widely utilized linear-quadratic (LQ) model. In this study, a large dataset of dose-response data was analysed, and the LQ model was found to provide the best description of the response to radiotherapy, with some variations observed for intermediate-risk patients. Additionally, the study investigated the radiobiological response of prostate cancer according to risk and the addition of ADT to treatment.
Article
Biochemistry & Molecular Biology
Carlos Casas-Arozamena, Alexandra Cortegoso, Raquel Pineiro-Perez, Alicia Abalo, Efigenia Arias, Victoria Sampayo, Ana Vilar, Marta Bouso, Eva Diaz, Gema Moreno-Bueno, Rafael Lopez-Lopez, Laura Muinelo-Romay, Miguel Abal, Juan Cueva
Summary: Endometrial cancer is a common malignancy in the female reproductive tract, and current therapeutic options are limited. This study demonstrates the value of liquid biopsy analysis in evaluating tumor evolution and utilizing uterine aspirate for comprehensive genomic profiling to identify potential therapeutic options.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Dentistry, Oral Surgery & Medicine
Manuel Eros Rodriguez-Fuentes, Mario Perez-Sayans, Luis Alberto Chauca-Bajana, Gema Barbeito-Castineiras, Maria Luisa Perez del Molino-Bernal, Rafael Lopez-Lopez
Summary: Oral mucositis is a common side effect in cancer patients receiving systemic antineoplastics. The underlying biological mechanisms leading to this condition are still unclear, but it has been hypothesized that systemic antineoplastics may cause an imbalance in the oral microbiota, subsequently triggering oral mucosa damage. However, there is currently insufficient scientific evidence regarding oral microbiological changes in patients undergoing systemic antineoplastics, and further investigations are needed.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
(2022)
Article
Oncology
Juan de la Haba-rodriguez, Ferran Ferragut Lloret, Maria Angeles Vaz Salgado, Martin Ore Arce, Ana Cardena Gutierrez, Jesus Garcia-Donas Jimenez, Carmen Beato Zambrano, Rosa Maria Rodriguez Alonso, Rafael Lopez Lopez, Nuria Rodriguez Salas
Summary: The improvement of molecular alterations in cancer and the development of technology have allowed us to more accurately determine molecular alterations in the diagnosis and treatment of cancer in clinical practice. The use of multidetermination platforms is becoming more widespread in Spanish hospitals. The objective of these clinical practice guides is to review their usefulness and establish guidelines for their incorporation into clinical practice.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)